Scarica l'app Stockscreener
39.39
0.43%
-0.17
Dopo l'orario di chiusura:
39.64
0.25
+0.63%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché MRNA Giù?
Forum
Previsione
Precedente Chiudi:
$39.56
Aprire:
$39.2
Volume 24 ore:
24.34M
Relative Volume:
3.35
Capitalizzazione di mercato:
$15.16B
Reddito:
$5.06B
Utile/perdita netta:
$-2.22B
Rapporto P/E:
-4.2128
EPS:
-9.35
Flusso di cassa netto:
$-3.96B
1 W Prestazione:
-5.83%
1M Prestazione:
+6.63%
6M Prestazione:
-70.69%
1 anno Prestazione:
-54.30%
Intervallo 1D:
$39.12
$40.83
Intervallo di 1 settimana:
$37.44
$44.38
Portata 52W:
$35.80
$170.47
Moderna Inc Stock (MRNA) Company Profile
Nome
Moderna Inc
Settore
Industria
Telefono
(617) 714-6500
Indirizzo
325 BINNEY STREET, CAMBRIDGE
Confronta MRNA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
39.39 | 15.16B | 5.06B | -2.22B | -3.96B | -5.82 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-18 | Downgrade | Argus | Buy → Hold |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-19 | Iniziato | Berenberg | Hold |
| 2024-11-18 | Aggiornamento | HSBC Securities | Hold → Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Underperform |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-09-13 | Downgrade | JP Morgan | Neutral → Underweight |
| 2024-09-13 | Downgrade | Jefferies | Buy → Hold |
| 2024-09-13 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-08-28 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-08-07 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2024-08-05 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-02-26 | Downgrade | HSBC Securities | Hold → Reduce |
| 2024-01-02 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2023-11-29 | Iniziato | Canaccord Genuity | Hold |
| 2023-11-03 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-11-02 | Downgrade | Deutsche Bank | Hold → Sell |
| 2023-08-04 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-08-03 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-07-24 | Iniziato | William Blair | Mkt Perform |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-06-26 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-26 | Iniziato | Guggenheim | Neutral |
| 2023-03-13 | Aggiornamento | TD Cowen | Market Perform → Outperform |
| 2023-03-02 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-02-24 | Downgrade | SVB Securities | Market Perform → Underperform |
| 2022-12-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-12-14 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2022-10-21 | Aggiornamento | SVB Leerink | Underperform → Mkt Perform |
| 2022-09-08 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2022-02-01 | Aggiornamento | Redburn | Sell → Neutral |
| 2022-01-26 | Aggiornamento | Deutsche Bank | Sell → Hold |
| 2022-01-21 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-01-21 | Iniziato | UBS | Neutral |
| 2021-12-07 | Iniziato | Cowen | Market Perform |
| 2021-11-09 | Iniziato | Wolfe Research | Outperform |
| 2021-10-22 | Iniziato | Deutsche Bank | Sell |
| 2021-10-15 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2021-08-06 | Downgrade | Oppenheimer | Outperform → Perform |
| 2021-08-06 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-07-15 | Reiterato | Jefferies | Hold |
| 2021-02-01 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-12-16 | Downgrade | Jefferies | Buy → Hold |
| 2020-12-16 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-09 | Downgrade | Needham | Buy → Hold |
| 2020-11-23 | Iniziato | Wells Fargo | Equal Weight |
| 2020-11-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-08 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2020-07-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2020-07-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-07-13 | Iniziato | Jefferies | Buy |
| 2020-06-30 | Iniziato | Argus | Buy |
| 2020-06-08 | Iniziato | Barclays | Overweight |
| 2020-04-30 | Iniziato | BMO Capital Markets | Outperform |
| 2020-03-05 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2019-12-03 | Ripresa | BofA/Merrill | Buy |
| 2019-10-25 | Iniziato | ROTH Capital | Buy |
| 2019-04-05 | Iniziato | Chardan Capital Markets | Buy |
Mostra tutto
Moderna Inc Borsa (MRNA) Ultime notizie
Moderna Inc. stock underperforms Friday when compared to competitors - MarketWatch
California’s bird flu emergency spotlights need for advanced therapeutics - Proactive Investors UK
Is Moderna Stock a Buy? - MSN
3 Stocks That Could Turn $1,000 into $5,000 by 2030 - The Motley Fool
Moderna Inc. stock outperforms competitors on strong trading day - MarketWatch
Moderna, Inc. (MRNA) Faces Criticism from Cramer Amid High R&D Spending and Revenue Struggles - Insider Monkey
Personalis Secures $50M from Merck, Extends Collaboration with Moderna - HIT Consultant
RNA Therapy Clinical Trials Market to Reach USD 4.16 Billion to 2034 - BioSpace
Merck Buys $50 Million of Personalis Stock - Marketscreener.com
Personalis Lands $50M Merck Investment, Extends Key Moderna Partnership for Cancer Therapy Platform - StockTitan
Moderna, Inc. (NASDAQ:MRNA) Shares Sold by Stifel Financial Corp - MarketBeat
Moderna Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Moderna lowered to hold at Argus amid lower COVID vaccine sales, competitive RSV market - MSN
Argus downgrades Moderna to hold on weak near-term outlook - MSN
This Feels Like the Post-Pandemic Rally. 3 Stocks to Buy If It Is - 24/7 Wall St.
Moderna shares downgraded to hold from buy by Argus on revenue decline - Investing.com
Argus Downgrades Moderna (NASDAQ:MRNA) to Hold - MarketBeat
Hedge Funds Think That Moderna, Inc. (MRNA) Will Bounce Back Soon - Insider Monkey
Moderna: Cutting Costs Might Not Be Enough (NASDAQ:MRNA) - Seeking Alpha
Moderna Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Moderna Halts mRNA RSV Vaccine Trial for Children After Five Infants were Hospitalized - WCBM
Analysts Tell Moderna Investors to Hold After 2024’s Steep Drop - BioSpace
Moderna Inc. stock rises Monday, still underperforms market - MarketWatch
What's Going On With Moderna Stock On Monday? - Yahoo Finance
Moderna remains the most shorted among S&P 500 healthcare stocks in November - MSN
What's Going On With Super Micro Computer Shares Monday? - Benzinga
Some Of This Year’s Big Losers Look Good To Me - Forbes
Moderna Continues To Slide YTD with Stock (MRNA) Down 62% - AskTraders
Is Moderna Stock Underperforming the Dow? - Nasdaq
Is Moderna Stock Underperforming The Dow? - Barchart
Five things: Editas cuts, CVS shares, Moderna's name and the best birthday gift ever - The Business Journals
Adult Vaccines Market Generated Opportunities, Future Scope - openPR
MicroStrategy, Palantir added to Nasdaq 100, with Moderna facing an exit - The Star Online
Cambridge drugmaker wins city approval to put its sign above the treeline - The Business Journals
Quantinno Capital Management LP Cuts Stock Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Moderna, Inc. of Class Action Lawsuit and Upcoming DeadlinesMRNA - Victoria Advocate
Toronto Dominion Bank Raises Holdings in Moderna, Inc. (NASDAQ:MRNA) - MarketBeat
Saylor’s MicroStrategy Scores Again With Nasdaq 100 Addition - Yahoo Finance
MicroStrategy, Palantir, Axon Added To Nasdaq 100: Super Micro Computer, Moderna, Illumina Exit The Index - Benzinga
MicroStrategy, Palantir Added to Nasdaq 100, Moderna Removed - Bloomberg
Palantir, MicroStrategy Likely To Join Nasdaq 100; Will Moderna, Super Micro Get The Axe? - MSN
Moderna | History, Innovation, Challenges, & Facts - Britannica
‘Safety signal’ in Moderna’s RSV vaccine studies halts trials of other vaccines for childhood killer - Science
FDA panel seeks more data on RSV vaccine safety in infants - BioPharma Dive
Moderna's SWOT analysis: stock faces transition as covid vaccine demand wanes - Investing.com
Is Moderna Stock A Sell In December 2024 With Deep Losses Projected For The Fourth Quarter? - Yahoo! Voices
FDA Committee Calls For More Research After Moderna’s RSV Vaccine Safety Issues - BioSpace
Moderna, Inc. (NASDAQ:MRNA) Shares Bought by Geode Capital Management LLC - MarketBeat
The specter of RFK Jr. has investors fretting about a onetime vaccine wunderkind - Yahoo Canada Finance
Moderna, Inc. (NASDAQ:MRNA) Receives $79.50 Consensus Price Target from Analysts - MarketBeat
Moderna Fires Back With Counterclaims In GSK RSV Vax Suit - Law360
Moderna Inc Azioni (MRNA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.16%
2.65%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):